National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in taiwan: A preliminary report

CHIA-HSUIN CHANGJOU-WEI LINWu L.-C.Liu C.-H.Lai M.-S.2020-10-152020-10-1520130025-7079https://www.scopus.com/inward/record.uri?eid=2-s2.0-84884819361&doi=10.1097%2fMLR.0b013e3182a502ba&partnerID=40&md5=cd38b5f447018ff228e8a6adc9153eabhttps://scholars.lib.ntu.edu.tw/handle/123456789/517151BACKGROUND[SDGs]SDG3adefovir; alpha2a interferon; alpha2b interferon; antivirus agent; entecavir; lamivudine; peginterferon alpha2a; peginterferon alpha2b; ribavirin; telbivudine; tenofovir; adult; aged; antiviral therapy; article; cancer incidence; cancer mortality; cancer registry; data base; female; hepatitis B; hepatitis C; human; liver cell carcinoma; major clinical study; male; national health insurance; priority journal; Taiwan; time series analysis; Adult; Age Distribution; Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Comorbidity; Female; Hepatitis B; Hepatitis C; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Sex Distribution; State Medicine; Survival Rate; TaiwanNational antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in taiwan: A preliminary reportjournal article10.1097/MLR.0b013e3182a502ba239695912-s2.0-84884819361